1
|
Joseph‐Mathurin N, Feldman RL, Lu R, Shirzadi Z, Toomer C, Saint Clair JR, Ma Y, McKay NS, Strain JF, Kilgore C, Friedrichsen KA, Chen CD, Gordon BA, Chen G, Hornbeck RC, Massoumzadeh P, McCullough AA, Wang Q, Li Y, Wang G, Keefe SJ, Schultz SA, Cruchaga C, Preboske GM, Jack CR, Llibre‐Guerra JJ, Allegri RF, Ances BM, Berman SB, Brooks WS, Cash DM, Day GS, Fox NC, Fulham M, Ghetti B, Johnson KA, Jucker M, Klunk WE, la Fougère C, Levin J, Niimi Y, Oh H, Perrin RJ, Reischl G, Ringman JM, Saykin AJ, Schofield PR, Su Y, Supnet‐Bell C, Vöglein J, Yakushev I, Brickman AM, Morris JC, McDade E, Xiong C, Bateman RJ, Chhatwal JP, Benzinger TLS. Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage. Alzheimers Dement 2024; 20:2680-2697. [PMID: 38380882 PMCID: PMC11032566 DOI: 10.1002/alz.13729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 12/19/2023] [Accepted: 12/21/2023] [Indexed: 02/22/2024]
Abstract
INTRODUCTION Amyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin-1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre-/postcodon 200) influences these pathologic features and dementia at different stages. METHODS Individuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments. We cross-sectionally evaluated regional Pittsburgh compound B-positron emission tomography uptake, magnetic resonance imaging markers of SVD (diffusion tensor imaging-based white matter injury, white matter hyperintensity volumes, and microhemorrhages), and cognition. RESULTS Postcodon 200 carriers had lower amyloid burden in all regions but worse markers of SVD and worse Clinical Dementia Rating® scores compared to precodon 200 carriers as a function of estimated years to symptom onset. Markers of SVD partially mediated the mutation position effects on clinical measures. DISCUSSION We demonstrated the genotypic variability behind spatiotemporal amyloidosis, SVD, and clinical presentation in DIAD, which may inform patient prognosis and clinical trials. HIGHLIGHTS Mutation position influences Aβ burden, SVD, and dementia. PSEN1 pre-200 group had stronger associations between Aβ burden and disease stage. PSEN1 post-200 group had stronger associations between SVD markers and disease stage. PSEN1 post-200 group had worse dementia score than pre-200 in late disease stage. Diffusion tensor imaging-based SVD markers mediated mutation position effects on dementia in the late stage.
Collapse
|
2
|
Rahmani F, Brier MR, Gordon BA, McKay N, Flores S, Keefe S, Hornbeck R, Ances B, Joseph‐Mathurin N, Xiong C, Wang G, Raji CA, Libre‐Guerra JJ, Perrin RJ, McDade E, Daniels A, Karch C, Day GS, Brickman AM, Fulham M, Jack CR, la La Fougère C, Reischl G, Schofield PR, Oh H, Levin J, Vöglein J, Cash DM, Yakushev I, Ikeuchi T, Klunk WE, Morris JC, Bateman RJ, Benzinger TLS. T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease. Hum Brain Mapp 2023; 44:6375-6387. [PMID: 37867465 PMCID: PMC10681640 DOI: 10.1002/hbm.26514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 09/17/2023] [Accepted: 09/27/2023] [Indexed: 10/24/2023] Open
Abstract
Carriers of mutations responsible for dominantly inherited Alzheimer disease provide a unique opportunity to study potential imaging biomarkers. Biomarkers based on routinely acquired clinical MR images, could supplement the extant invasive or logistically challenging) biomarker studies. We used 1104 longitudinal MR, 324 amyloid beta, and 87 tau positron emission tomography imaging sessions from 525 participants enrolled in the Dominantly Inherited Alzheimer Network Observational Study to extract novel imaging metrics representing the mean (μ) and standard deviation (σ) of standardized image intensities of T1-weighted and Fluid attenuated inversion recovery (FLAIR) MR scans. There was an exponential decrease in FLAIR-μ in mutation carriers and an increase in FLAIR and T1 signal heterogeneity (T1-σ and FLAIR-σ) as participants approached the symptom onset in both supramarginal, the right postcentral and right superior temporal gyri as well as both caudate nuclei, putamina, thalami, and amygdalae. After controlling for the effect of regional atrophy, FLAIR-μ decreased and T1-σ and FLAIR-σ increased with increasing amyloid beta and tau deposition in numerous cortical regions. In symptomatic mutation carriers and independent of the effect of regional atrophy, tau pathology demonstrated a stronger relationship with image intensity metrics, compared with amyloid pathology. We propose novel MR imaging intensity-based metrics using standard clinical T1 and FLAIR images which strongly associates with the progression of pathology in dominantly inherited Alzheimer disease. We suggest that tau pathology may be a key driver of the observed changes in this cohort of patients.
Collapse
Affiliation(s)
| | | | - Brian A. Gordon
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Nicole McKay
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Shaney Flores
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Sarah Keefe
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Russ Hornbeck
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Beau Ances
- Washington University School of MedicineSt. LouisMissouriUSA
| | | | - Chengjie Xiong
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Guoqiao Wang
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Cyrus A. Raji
- Washington University School of MedicineSt. LouisMissouriUSA
| | | | | | - Eric McDade
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Alisha Daniels
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Celeste Karch
- Washington University School of MedicineSt. LouisMissouriUSA
| | - Gregory S. Day
- Mayo Clinic, Department of NeurologyJacksonvilleFloridaUSA
| | - Adam M. Brickman
- Taub Institute for Research on Alzheimer's Disease & the Aging Brain, and Department of Neurology College of Physicians and SurgeonsColumbia UniversityNew YorkNew YorkUSA
| | | | | | - Christian la La Fougère
- Department of Nuclear Medicine and Clinical Molecular ImagingUniversity Hospital TuebingenTübingenGermany
- German Center for Neurodegenerative Diseases (DZNE) TuebingenTübingenGermany
- Department of Preclinical Imaging and RadiopharmacyEberhard Karls University TübingenTübingenGermany
| | - Gerald Reischl
- Department of Nuclear Medicine and Clinical Molecular ImagingUniversity Hospital TuebingenTübingenGermany
- German Center for Neurodegenerative Diseases (DZNE) TuebingenTübingenGermany
- Department of Preclinical Imaging and RadiopharmacyEberhard Karls University TübingenTübingenGermany
| | - Peter R. Schofield
- Neuroscience Research AustraliaSydneyNew South WalesAustralia
- School of Biomedical SciencesUniversity of New South WalesSydneyNew South WalesAustralia
| | - Hwamee Oh
- Brown UniversityProvidenceRhode IslandUSA
| | - Johannes Levin
- Department of NeurologyLudwig‐Maximilians‐Universität MünchenMunichGermany
- German Center for Neurodegenerative Diseases (DZNE), site MunichMunichGermany
- Munich Cluster for Systems Neurology (SyNergy)MunichGermany
| | - Jonathan Vöglein
- Department of NeurologyLudwig‐Maximilians‐Universität MünchenMunichGermany
- German Center for Neurodegenerative Diseases (DZNE), site MunichMunichGermany
- Munich Cluster for Systems Neurology (SyNergy)MunichGermany
| | - David M. Cash
- UK Dementia Research Institute at University College LondonLondonUK
- Dementia Research CentreUCL Queen Square Institute of NeurologyLondonUK
| | - Igor Yakushev
- Department of NeurologyLudwig‐Maximilians‐Universität MünchenMunichGermany
- German Center for Neurodegenerative Diseases (DZNE), site MunichMunichGermany
- Munich Cluster for Systems Neurology (SyNergy)MunichGermany
| | | | | | - John C. Morris
- Washington University School of MedicineSt. LouisMissouriUSA
| | | | | | | |
Collapse
|
3
|
Schultz SA, Shirzadi Z, Schultz AP, Liu L, Fitzpatrick CD, McDade E, Barthelemy NR, Renton A, Esposito B, Joseph‐Mathurin N, Cruchaga C, Chen CD, Goate A, Allegri RF, Benzinger TLS, Berman S, Chui HC, Fagan AM, Farlow MR, Fox NC, Gordon BA, Day GS, Graff‐Radford NR, Hassenstab JJ, Hanseeuw BJ, Hofmann A, Jack CR, Jucker M, Karch CM, Koeppe RA, Lee J, Levey AI, Levin J, Martins RN, Mori H, Morris JC, Noble J, Perrin RJ, Rosa‐Neto P, Salloway SP, Sanchez‐Valle R, Schofield PR, Xiong C, Johnson KA, Bateman RJ, Sperling RA, Chhatwal JP. Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal-dominant Alzheimer's disease. Aging Cell 2023; 22:e13871. [PMID: 37291760 PMCID: PMC10410059 DOI: 10.1111/acel.13871] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/30/2023] [Accepted: 05/03/2023] [Indexed: 06/10/2023] Open
Abstract
Although pathogenic variants in PSEN1 leading to autosomal-dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non-carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre-symptomatic and symptomatic phases of disease as compared to CY, using both cross-sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ-secretase and the generation of toxic β-amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.
Collapse
Affiliation(s)
| | - Zahra Shirzadi
- Massachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Aaron P. Schultz
- Massachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
| | - Lei Liu
- Brigham and Women's HospitalBostonMassachusettsUSA
- Ann Romney Center for Neurologic DiseasesBostonMassachusettsUSA
| | | | - Eric McDade
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | | | - Alan Renton
- Department of Genetics and Genomic SciencesIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | - Bianca Esposito
- Department of Genetics and Genomic SciencesIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | | | - Carlos Cruchaga
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Charles D. Chen
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Alison Goate
- Department of Genetics and Genomic SciencesIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | | | | | - Sarah Berman
- University of PittsburghPittsburghPennsylvaniaUSA
| | - Helena C. Chui
- Department of Neurology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Anne M. Fagan
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Martin R. Farlow
- Indiana Alzheimer's Disease Research CenterIndianapolisIndianaUSA
| | - Nick C. Fox
- Dementia Research Centre & UK Dementia Research InstituteUCL Institute of NeurologyLondonUK
| | - Brian A. Gordon
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | | | | | | | - Bernard J. Hanseeuw
- Institute of Neuroscience, UCLouvainBrusselsBelgium
- Gordon Center for Medical Imaging in the Radiology Department of MGHBostonMassachusettsUSA
| | - Anna Hofmann
- German Center for Neurodegenerative Diseases (DZNE)TuebingenGermany
| | | | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE)TuebingenGermany
| | - Celeste M. Karch
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | | | - Jae‐Hong Lee
- Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
| | - Allan I. Levey
- Emory Goizueta Alzheimer's Disease Research CenterAtlantaGeorgiaUSA
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE)MunichGermany
- Department of NeurologyLudwig‐Maximilians‐Universität MünchenMunichGermany
- Munich Cluster for Systems Neurology (SyNergy)MunichGermany
| | | | | | - John C. Morris
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | | | - Richard J. Perrin
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Pedro Rosa‐Neto
- Translational Neuroimaging Laboratory, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest‐de‐l'Île‐de‐Montréal; Department of Neurology and NeurosurgeryMcGill UniversityMontrealCanada
| | | | - Raquel Sanchez‐Valle
- Alzheimer's disease and other cognitive disorders Unit, Neurology Department, Hospital Clínic de BarcelonaInstitut d'Investigacions BiomediquesBarcelonaSpain
| | - Peter R. Schofield
- Neuroscience Research AustraliaRandwickNew South WalesAustralia
- School of Medical SciencesUniversity of New South WalesSydneyNew South WalesAustralia
| | - Chengjie Xiong
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Keith A. Johnson
- Massachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Brigham and Women's HospitalBostonMassachusettsUSA
| | - Randall J. Bateman
- Washington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Reisa A. Sperling
- Massachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Brigham and Women's HospitalBostonMassachusettsUSA
| | - Jasmeer P. Chhatwal
- Massachusetts General Hospital, Harvard Medical SchoolBostonMassachusettsUSA
- Brigham and Women's HospitalBostonMassachusettsUSA
| | | |
Collapse
|
4
|
Shirzadi Z, Schultz SA, Yau WW, Joseph‐Mathurin N, Kantarci K, Preboske GM, Jack CR, Farlow MR, Fagan AM, Hassenstab JJ, Jucker M, Morris JC, Xiong C, Karch CM, Fitzpatrick CD, Levey AI, Gordon BA, Schofield PW, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Graff‐Radford NR, Koeppe R, Noble JM, Chui HC, Berman S, Mori H, Sanchez‐Valle R, Lee J, Rosa‐Neto P, Benzinger TL, Sohrabi HR, Martins RN, Schultz AP, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Chhatwal JP. Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration. Alzheimers Dement 2022. [DOI: 10.1002/alz.066715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Zahra Shirzadi
- Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | - Stephanie A. Schultz
- Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | | | | | | | | | | | | | - Anne M. Fagan
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE) Tuebingen Germany
| | - John C. Morris
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Chengjie Xiong
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Celeste M. Karch
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Brian A. Gordon
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Richard J. Perrin
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Eric McDade
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE) Munich Germany
| | | | | | - Nick C Fox
- UK Dementia Research Institute, UCL London United Kingdom
| | - Alison Goate
- Icahn School of Medicine at Mount Sinai New York City NY USA
| | | | | | | | - Helena C Chui
- University of Southern California Los Angeles CA USA
| | | | - Hiroshi Mori
- Osaka City University Medical School Osaka Japan
| | | | - Jae‐Hong Lee
- Asan Medical Center, University of Ulsan College of Medicine Seoul Korea, Republic of (South)
| | - Pedro Rosa‐Neto
- Montreal Neurological Institute, McGill University Montreal QC Canada
| | | | - Hamid R Sohrabi
- Department of Biomedical Sciences, Macquarie University Sydney NSW Australia
| | - Ralph N Martins
- Edith Cowan University Joondalup Western Australia Australia
| | - Aaron P. Schultz
- Massachusetts General Hospital, Harvard Medical School Boston MA USA
| | | | - Keith A. Johnson
- Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | - Reisa A. Sperling
- Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | | | | | | |
Collapse
|
5
|
Schultz SA, Allegri RF, Schultz AP, Goate A, Levey AI, Fagan AM, Hanseeuw BJ, Koeppe RA, Gordon BA, Cruchaga C, Karch CM, Chen CD, Xiong C, Jack CR, Fitzpatrick CD, McDade E, Chui HC, Mori H, Lee J, Noble JM, Hassenstab JJ, Levin J, Morris JC, Johnson KA, Liu L, Farlow MR, Jucker M, Farrell ME, Graff‐Radford NR, Joseph‐Mathurin N, Fox NC, Schofield PR, Martins RN, Sanchez‐Valle R, Perrin RJ, Berman S, Salloway SP, Shirzadi Z, Rosa‐Neto P, Benzinger TL, Bateman RJ, Sperling RA, Chhatwal JP. AD‐causing variants that affect
PSEN1
transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. Alzheimers Dement 2022. [DOI: 10.1002/alz.068221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Stephanie A. Schultz
- Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | | | - Aaron P. Schultz
- Massachusetts General Hospital, Harvard Medical School Boston MA USA
| | - Alison Goate
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai New York NY USA
| | - Allan I. Levey
- Emory Goizueta Alzheimer's Disease Research Center Atlanta GA USA
| | - Anne M. Fagan
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Bernard J Hanseeuw
- Institute of Neuroscience, UCLouvain Brussels Belgium
- Massachussets General Hospital, Harvard Medical School Boston USA
| | | | - Brian A. Gordon
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Celeste M. Karch
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Charles D. Chen
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Chengjie Xiong
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Eric McDade
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Helena C Chui
- Department of Neurology, Keck School of Medicine, University of Southern California Los Angeles CA USA
| | - Hiroshi Mori
- Osaka City University Medical School Osaka Japan
| | - Jae‐Hong Lee
- Asan Medical Center, University of Ulsan College of Medicine Seoul Korea, Republic of (South)
| | | | | | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE) Munich Germany
| | - John C. Morris
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Keith A. Johnson
- Massachusetts General Hospital, Harvard Medical School Boston MA USA
| | - Lei Liu
- Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | | | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE) Tuebingen Germany
| | | | | | | | - Nick C Fox
- University College London Institute of Neurology London United Kingdom
| | | | - Ralph N Martins
- Edith Cowan University Joondalup Western Australia Australia
| | - Raquel Sanchez‐Valle
- Neurology Department, Hospital Clínic. Institut d'Investigacions Biomediques Barcelona Spain
| | - Richard J. Perrin
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Zahra Shirzadi
- Massachusetts General Hospital, Brigham and Women’s Hospital,Harvard Medical School Boston MA USA
| | | | | | | | - Reisa A. Sperling
- Massachusetts General Hospital, Harvard Medical School Boston MA USA
| | | |
Collapse
|
6
|
Schultz SA, Allegri RF, Schultz AP, Goate A, Levey AI, Fagan AM, Hanseeuw BJ, Koeppe RA, Gordon BA, Cruchaga C, Karch CM, Chen CD, Xiong C, Jack CR, Fitzpatrick CD, McDade E, Chui HC, Mori H, Lee J, Noble JM, Hassenstab JJ, Levin J, Morris JC, Johnson KA, Liu L, Farlow MR, Jucker M, Farrell ME, Graff‐Radford NR, Joseph‐Mathurin N, Fox NC, Schofield PR, Martins RN, Sanchez‐Valle R, Perrin RJ, Berman S, Salloway SP, Shirzadi Z, Rosa‐Neto P, Benzinger TL, Bateman RJ, Sperling RA, Chhatwal JP. AD‐causing variants that affect
PSEN1
transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. Alzheimers Dement 2022. [DOI: 10.1002/alz.067186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Stephanie A. Schultz
- Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | | | | | - Alison Goate
- Icahn School of Medicine at Mount Sinai New York NY USA
| | - Allan I. Levey
- Emory Goizueta Alzheimer's Disease Research Center Atlanta GA USA
| | - Anne M. Fagan
- Washington University in St. Louis, St. Louis MO USA
- Knight Alzheimer Disease Research Center, St. Louis MO USA
| | | | | | - Brian A. Gordon
- Knight Alzheimer Disease Research Center, St. Louis MO USA
- Washington University School of Medicine, St. Louis MO USA
| | - Carlos Cruchaga
- Knight Alzheimer Disease Research Center, St. Louis MO USA
- Washington University School of Medicine St Louis MO USA
| | - Celeste M. Karch
- Washington University in St. Louis School of Medicine, St. Louis MO USA
| | | | - Chengjie Xiong
- Washington University in St. Louis, St. Louis MO USA
- Knight Alzheimer Disease Research Center, St. Louis MO USA
| | | | | | - Eric McDade
- Washington University School of Medicine, St. Louis MO USA
| | | | - Hiroshi Mori
- Osaka City University Medical School Osaka Japan
| | - Jae‐Hong Lee
- Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of (South)
| | | | | | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE) Munich Germany
| | - John C. Morris
- Washington University School of Medicine, St. Louis MO USA
| | - Keith A. Johnson
- Massachusetts General Hospital, Brigham and Women’s Hospital,Harvard Medical School Boston MA USA
| | - Lei Liu
- Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School Boston MA USA
| | | | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE) Tuebingen Germany
| | | | | | | | - Nick C Fox
- Dementia Research Centre, UCL Queen Square Institute of Neurology London United Kingdom
| | | | - Ralph N Martins
- Edith Cowan University, Joondalup Western Australia Australia
| | - Raquel Sanchez‐Valle
- Neurology Department, Hospital Clínic. Institut d'Investigacions Biomediques Barcelona Spain
| | - Richard J. Perrin
- Washington University in St. Louis School of Medicine, St. Louis MO USA
| | | | | | - Zahra Shirzadi
- Massachusetts General Hospital, Brigham and Women’s Hospital,Harvard Medical School Boston MA USA
| | - Pedro Rosa‐Neto
- Montreal Neurological Institute, McGill University Montreal QC Canada
| | - Tammie L.S. Benzinger
- Knight Alzheimer Disease Research Center, St. Louis MO USA
- Washington University School of Medicine, St. Louis MO USA
| | | | | | - Jasmeer P. Chhatwal
- Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Harvard Medical School Boston MA USA
| |
Collapse
|
7
|
Joseph‐Mathurin N, Llibre‐Guerra JJ, Li Y, McCullough AA, Hofmann C, Wojtowicz J, Park E, Wang G, Preboske GM, Wang Q, Gordon BA, Chen CD, Flores S, Aggarwal NT, Berman SB, Bird TD, Black SE, Borowski B, Brooks WS, Chhatwal JP, Clarnette R, Cruchaga C, Fagan AM, Farlow M, Fox NC, Gauthier S, Hassenstab J, Hobbs DA, Holdridge KC, Honig LS, Hornbeck RC, Hsiung GR, Jack CR, Jimenez‐Velazquez IZ, Jucker M, Klein G, Levin J, Mancini M, Masellis M, McKay NS, Mummery CJ, Ringman JM, Shimada H, Snider BJ, Suzuki K, Wallon D, Xiong C, Yaari R, McDade E, Perrin RJ, Bateman RJ, Salloway SP, Benzinger TL, Clifford DB. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Ann Neurol 2022; 92:729-744. [PMID: 36151869 PMCID: PMC9828339 DOI: 10.1002/ana.26511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 09/12/2022] [Accepted: 09/15/2022] [Indexed: 01/12/2023]
Abstract
OBJECTIVE To determine the characteristics of participants with amyloid-related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD). METHODS 142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β-amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross-sectional and longitudinal analyses evaluated potential ARIA-related risk factors. RESULTS Eleven participants developed ARIA-E, including 3 with mild symptoms. No ARIA-E was reported under solanezumab while gantenerumab was associated with ARIA-E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE-ɛ4 carriers were more likely to develop ARIA-E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA-E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA-E occurrence, all ARIA-E participants were amyloid-PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA-H. Most ARIA-E radiologically resolved after dose adjustment and developing ARIA-E did not significantly increase odds of trial discontinuation. ARIA-E was more frequently observed in the occipital lobe (90%). ARIA-E severity was associated with age at time of ARIA-E. INTERPRETATION In DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA-E risk, with additional risk for individuals APOE-ɛ4(+) or with microhemorrhage. ARIA-E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729-744.
Collapse
Affiliation(s)
- Nelly Joseph‐Mathurin
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | | | - Yan Li
- Department of NeurologyWashington University School of MedicineSt. LouisMO
| | - Austin A. McCullough
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - Carsten Hofmann
- Pharmaceutical Sciences, Roche Innovation Center BaselF. Hoffmann‐La Roche Ltd.BaselSwitzerland
| | - Jakub Wojtowicz
- Product Development, Clinical SafetyF. Hoffmann‐La Roche Ltd.BaselSwitzerland
| | - Ethan Park
- Division of BiostatisticsWashington University School of MedicineSt. LouisMO
| | - Guoqiao Wang
- Division of BiostatisticsWashington University School of MedicineSt. LouisMO
| | | | - Qing Wang
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - Brian A. Gordon
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - Charles D. Chen
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - Shaney Flores
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - Neelum T. Aggarwal
- Department of Neurological SciencesRush University Medical CenterChicagoIL
| | - Sarah B. Berman
- Departments of Neurology and Clinical and Translational ScienceUniversity of PittsburghPittsburghPA
| | - Thomas D. Bird
- Department of NeurologyUniversity of WashingtonSeattleWA
| | - Sandra E. Black
- Department of Medicine (Neurology), Sunnybrook Health Sciences CentreSunnybrook Research Institute, University of TorontoTorontoOntarioCanada
| | | | - William S. Brooks
- Neuroscience Research AustraliaUniversity of New South WalesNew South WalesAustralia
| | - Jasmeer P. Chhatwal
- Department of NeurologyBrigham and Women's Hospital, Massachusetts General HospitalBostonMA
| | - Roger Clarnette
- Department of Internal Medicine, Medical SchoolUniversity of Western AustraliaCrawleyAustralia
| | - Carlos Cruchaga
- Department of PsychiatryWashington University School of MedicineSt. LouisMO
| | - Anne M. Fagan
- Department of NeurologyWashington University School of MedicineSt. LouisMO
| | - Martin Farlow
- Department of NeurologyIndiana University School of MedicineIndianapolisIN
| | - Nick C. Fox
- UCL Queen Square Institute of NeurologyUniversity College LondonLondonUK
| | - Serge Gauthier
- McGill Center for Studies in AgingMcGill UniversityMontrealQuebecCanada
| | - Jason Hassenstab
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
- Psychological and Brain SciencesWashington University School of MedicineSt. LouisMO
| | - Diana A. Hobbs
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | | | | | - Russ C. Hornbeck
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - Ging‐Yuek R. Hsiung
- Department of MedicineUniversity of British ColumbiaVancouverBritish ColumbiaCanada
| | | | | | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE)Hertie Institute for Clinical Brain Research, University of TübingenTübingenGermany
| | - Gregory Klein
- Clinical Imaging, Biomarkers & Translational TechnologiesF. Hoffmann‐La Roche Ltd.BaselSwitzerland
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE), Department of Neurology, Ludwig‐Maximilians‐Universität MünchenMunich Cluster for Systems Neurology (SyNergy)MunichGermany
| | | | - Mario Masellis
- Department of Medicine (Neurology), Sunnybrook Health Sciences CentreSunnybrook Research Institute, University of TorontoTorontoOntarioCanada
| | - Nicole S. McKay
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | | | - John M. Ringman
- Department of Neurology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCA
| | - Hiroyuki Shimada
- Diagnostic and Interventional Radiology, Graduate School of MedicineOsaka City UniversityOsakaJapan
| | - B. Joy Snider
- Department of NeurologyWashington University School of MedicineSt. LouisMO
| | - Kazushi Suzuki
- Department of Internal MedicineNational Defense Medical CollegeSaitamaJapan
| | | | - Chengjie Xiong
- Division of BiostatisticsWashington University School of MedicineSt. LouisMO
| | | | - Eric McDade
- Department of NeurologyWashington University School of MedicineSt. LouisMO
| | - Richard J. Perrin
- Department of NeurologyWashington University School of MedicineSt. LouisMO
- Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMO
| | - Randall J. Bateman
- Department of NeurologyWashington University School of MedicineSt. LouisMO
| | - Stephen P. Salloway
- Department of NeurologyAlpert Medical School of Brown University, Butler HospitalProvidenceRI
| | - Tammie L.S. Benzinger
- Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisMO
| | - David B. Clifford
- Department of NeurologyWashington University School of MedicineSt. LouisMO
| | | |
Collapse
|
8
|
Wang G, Li Y, Xiong C, McDade E, Clifford DB, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TL, Gordon BA, Fagan AM, Coalier KA, Libre‐Guerra JJ, McCullough A, Joseph‐Mathurin N, Chen CD, Mummery C, Wendelberger BA, Gauthier S, Masellis M, Holdridge KC, Yaari R, Chatterjee S, Sims J, Delmar P, Kerchner GA, Bittner T, Hofmann C, Bateman RJ. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Alzheimers Dement (Amst) 2022; 14:e12367. [PMID: 36348972 PMCID: PMC9632865 DOI: 10.1002/dad2.12367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 09/21/2022] [Accepted: 09/28/2022] [Indexed: 11/05/2022]
Abstract
Introduction While the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) was ongoing, external data suggested higher doses were needed to achieve targeted effects; therefore, doses of gantenerumab were increased 5-fold, and solanezumab was increased 4-fold. We evaluated to what extent mid-trial dose increases produced a dose-dependent treatment effect. Methods Using generalized linear mixed effects (LME) models, we estimated the annual low- and high-dose treatment effects in clinical, cognitive, and biomarker outcomes. Results Both gantenerumab and solanezumab demonstrated dose-dependent treatment effects (significant for gantenerumab, non-significant for solanezumab) in their respective target amyloid biomarkers (Pittsburgh compound B positron emission tomography standardized uptake value ratio and cerebrospinal fluid amyloid beta 42), with gantenerumab demonstrating additional treatment effects in some downstream biomarkers. No dose-dependent treatment effects were observed in clinical or cognitive outcomes. Conclusions Mid-trial dose escalation can be implemented as a remedy for an insufficient initial dose and can be more cost effective and less burdensome to participants than starting a new trial with higher doses, especially in rare diseases. Highlights We evaluated the dose-dependent treatment effect of two different amyloid-specific immunotherapies.Dose-dependent treatment effects were observed in some biomarkers.No dose-dependent treatment effects were observed in clinical/cognitive outcomes, potentially due to the fact that the modified study may not have been powered to detect such treatment effects in symptomatic subjects at a mild stage of disease exposed to high (or maximal) doses of medication for prolonged durations.
Collapse
Affiliation(s)
- Guoqiao Wang
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Yan Li
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Chengjie Xiong
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Eric McDade
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - David B. Clifford
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Susan L. Mills
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Anna M. Santacruz
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | | | - Jason Hassenstab
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | | | - Brian A. Gordon
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Anne M. Fagan
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | - Kelley A. Coalier
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | | | - Austin McCullough
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | | | - Charles D. Chen
- Washington University St LouisSchool of MedicineSt. LouisMissouriUSA
| | | | | | - Serge Gauthier
- McGill University Centre for Studies on Aging in MontrealMontrealQuebecCanada
| | - Mario Masellis
- University of TorontoSunnybrook Health Sciences CentreTorontoOntarioCanada
| | | | - Roy Yaari
- Eli Lilly and CompanyIndianapolisIndianaUSA
| | | | - John Sims
- Eli Lilly and CompanyIndianapolisIndianaUSA
| | | | | | | | | | | | | |
Collapse
|
9
|
Schultz SA, Schultz AP, Joseph‐Mathurin N, McDade E, Klunk WE, Fox NC, Levin J, Hassenstab J, Goate AM, Hanseeuw BJ, Lee J, Fitzpatrick CD, Jucker M, Allegri RF, Benzinger TL, Berman S, Chui HC, Cruchaga C, Fagan AM, Gordon BA, Farlow MR, Graff‐Radford NR, Martins RN, Mori H, Noble J, Perrin RJ, Salloway SP, Sanchez‐Valle R, Schofield PR, Levey AI, Karch CM, Xiong C, Johnson KA, Bateman RJ, Sperling RA, Chhatwal JP. The location of
PSEN1
pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. Alzheimers Dement 2021. [DOI: 10.1002/alz.050864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
| | - Aaron P. Schultz
- Massachusetts General Hospital Harvard Medical School Department of Neurology Boston MA USA
| | | | - Eric McDade
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Nick C. Fox
- Dementia Research Centre London United Kingdom
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE) Munich Germany
| | - Jason Hassenstab
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Jae‐Hong Lee
- Asan Medical Center University of Ulsan College of Medicine Seoul South Korea
| | | | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE) Tuebingen Germany
| | | | | | - Sarah Berman
- University of Pittsburgh School of Medicine Pittsburgh PA USA
| | - Helena C. Chui
- Department of Neurology Keck School of Medicine University of Southern California Los Angeles CA USA
| | - Carlos Cruchaga
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Anne M. Fagan
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Brian A. Gordon
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | | | - Hiroshi Mori
- Osaka City University Medical School Osaka Japan
| | | | - Richard J. Perrin
- Washington University in St. Louis School of Medicine St Louis MO USA
| | | | - Raquel Sanchez‐Valle
- Neurology Department Hospital Clínic, Institut d'Investigacions Biomediques Barcelona Spain
| | | | - Allan I. Levey
- Emory Goizueta Alzheimer's Disease Research Center Atlanta GA USA
| | - Celeste M. Karch
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Chengjie Xiong
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Keith A. Johnson
- Massachusetts General Hospital Harvard Medical School Boston MA USA
| | | | | | | | | |
Collapse
|
10
|
Joseph‐Mathurin N, Feldman RL, Toomer C, McKay NS, Strain JF, Kilgore CB, Gordon BA, McCullough AA, Chen CD, Schultz SA, Cruchaga C, Xiong C, Morris JC, Bateman RJ, Chhatwal JP, Benzinger TL. PS1
mutation position influences regional PiB‐uptake and white matter lesion volume. Alzheimers Dement 2021. [DOI: 10.1002/alz.056566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | | | - Nicole S. McKay
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Jeremy F. Strain
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Collin B. Kilgore
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Brian A. Gordon
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Charles D. Chen
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Carlos Cruchaga
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Chengjie Xiong
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - John C. Morris
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | | | | |
Collapse
|
11
|
Chen CD, McCullough AA, Gordon BA, Joseph‐Mathurin N, Wang G, Li Y, Xiong C, Pontecorvo MJ, Klein G, Shcherbinin S, Higgins IA, Masters CL, Clifford DB, van Dyck CH, Masellis M, Hsiung GR, Gauthier S, Bateman RJ, McDade E, Salloway SP, Benzinger TL. [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance. Alzheimers Dement 2021. [DOI: 10.1002/alz.056094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | | | | | - Guoqiao Wang
- Washington University in St Louis St. Louis MO USA
| | - Yan Li
- Washington University School of Medicine St. Louis MO USA
| | | | | | | | | | | | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | - David B. Clifford
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | - Ging‐Yuek Robin Hsiung
- Djavad Mowafaghian Centre for Brain Health, University of British Colombia Vancouver BC Canada
| | - Serge Gauthier
- Douglas Mental Health University Institute Montréal QC Canada
| | | | - Eric McDade
- Washington University in St Louis St. Louis MO USA
| | | | | |
Collapse
|
12
|
Joseph‐Mathurin N, Llibre‐Guerra JJ, McCullough AA, Li Y, Hofmann C, Wojtowicz J, Wang Q, Wang G, Gordon BA, Chen CD, Brooks WS, Gauthier S, Holdridge KC, Hsiung GR, Jack CR, Klein G, Masellis M, Mummery CJ, Preboske GM, Santacruz A, Wallon D, Xiong C, Yaari R, McDade E, Bateman RJ, Salloway SP, Benzinger TL, Clifford DB. Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial. Alzheimers Dement 2021. [DOI: 10.1002/alz.056393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | | | | | - Yan Li
- Washington University School of Medicine St. Louis MO USA
| | | | | | - Qing Wang
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Guoqiao Wang
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Brian A. Gordon
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Charles D. Chen
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - William S. Brooks
- Neuroscience Research Australia Randwick NSW Australia
- University of New South Wales Kensington NSW Australia
| | | | | | | | | | | | | | | | | | - Anna Santacruz
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | - Chengjie Xiong
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | - Roy Yaari
- Eli Lilly and Company Indianapolis IN USA
| | - Eric McDade
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | | | | | | - David B. Clifford
- Washington University in St. Louis School of Medicine St. Louis MO USA
| | | |
Collapse
|
13
|
Keret O, Staffaroni AM, Ringman JM, Cobigo Y, Goh SM, Wolf A, Allen IE, Salloway S, Chhatwal J, Brickman AM, Reyes‐Dumeyer D, Bateman RJ, Benzinger TL, Morris JC, Ances BM, Joseph‐Mathurin N, Perrin RJ, Gordon BA, Levin J, Vöglein J, Jucker M, la Fougère C, Martins RN, Sohrabi HR, Taddei K, Villemagne VL, Schofield PR, Brooks WS, Fulham M, Masters CL, Ghetti B, Saykin AJ, Jack CR, Graff‐Radford NR, Weiner M, Cash DM, Allegri RF, Chrem P, Yi S, Miller BL, Rabinovici GD, Rosen HJ. Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimers Dement (Amst) 2021; 13:e12197. [PMID: 34258377 PMCID: PMC8256623 DOI: 10.1002/dad2.12197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 04/13/2021] [Indexed: 01/18/2023]
Abstract
INTRODUCTION Asymptomatic and mildly symptomatic dominantly inherited Alzheimer's disease mutation carriers (DIAD-MC) are ideal candidates for preventative treatment trials aimed at delaying or preventing dementia onset. Brain atrophy is an early feature of DIAD-MC and could help predict risk for dementia during trial enrollment. METHODS We created a dementia risk score by entering standardized gray-matter volumes from 231 DIAD-MC into a logistic regression to classify participants with and without dementia. The score's predictive utility was assessed using Cox models and receiver operating curves on a separate group of 65 DIAD-MC followed longitudinally. RESULTS Our risk score separated asymptomatic versus demented DIAD-MC with 96.4% (standard error = 0.02) and predicted conversion to dementia at next visit (hazard ratio = 1.32, 95% confidence interval [CI: 1.15, 1.49]) and within 2 years (area under the curve = 90.3%, 95% CI [82.3%-98.2%]) and improved prediction beyond established methods based on familial age of onset. DISCUSSION Individualized risk scores based on brain atrophy could be useful for establishing enrollment criteria and stratifying DIAD-MC participants for prevention trials.
Collapse
Affiliation(s)
- Ophir Keret
- Global Brain Health InstituteUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Adam M. Staffaroni
- Department of Neurology, Memory and Aging CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - John M. Ringman
- Alzheimer's Disease Research Center, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesCaliforniaUSA
| | - Yann Cobigo
- Department of Neurology, Memory and Aging CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Sheng‐Yang M. Goh
- Department of Neurology, Memory and Aging CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Amy Wolf
- Department of Neurology, Memory and Aging CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Isabel Elaine Allen
- Global Brain Health InstituteUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Stephen Salloway
- Warren Alpert Medical SchoolBrown UniversityProvidenceRhode IslandUSA
| | - Jasmeer Chhatwal
- Massachusetts General Hospital, Harvard Medical School BostonBostonMassachusettsUSA
| | - Adam M. Brickman
- Taub Institute for Research on Alzheimer's Disease and the Aging BrainColumbia UniversityNew YorkNew YorkUSA
| | - Dolly Reyes‐Dumeyer
- Taub Institute for Research on Alzheimer's Disease and the Aging BrainColumbia UniversityNew YorkNew YorkUSA
| | - Randal J. Bateman
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Neuropathology, Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Biostatistics, Department of PsychiatryWashington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Tammie L.S. Benzinger
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
| | - John C. Morris
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Neuropathology, Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Biostatistics, Department of PsychiatryWashington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Beau M. Ances
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Neuropathology, Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Biostatistics, Department of PsychiatryWashington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Nelly Joseph‐Mathurin
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Neuropathology, Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Biostatistics, Department of PsychiatryWashington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Richard J. Perrin
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Neuropathology, Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Biostatistics, Department of PsychiatryWashington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Brian A. Gordon
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of NeurologyWashington University School of MedicineSt. LouisMissouriUSA
- Department of RadiologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Neuropathology, Department of Pathology & ImmunologyWashington University School of MedicineSt. LouisMissouriUSA
- Division of Biostatistics, Department of PsychiatryWashington University in St. Louis School of MedicineSt. LouisMissouriUSA
| | - Johannes Levin
- German Center for Neurodegenerative Diseases (DZNE)MunichGermany
- Department of NeurologyLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Jonathan Vöglein
- German Center for Neurodegenerative Diseases (DZNE)MunichGermany
- Department of NeurologyLudwig‐Maximilians‐Universität MünchenMunichGermany
| | - Mathias Jucker
- German Center for Neurodegenerative Diseases (DZNE)TübingenGermany
- Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain ResearchUniversity of TübingenTübingenGermany
| | - Christian la Fougère
- German Center for Neurodegenerative Diseases (DZNE)TübingenGermany
- Institute for Nuclear Medicine and Clinical Molecular ImagingEberhard Karls UniversityTübingenGermany
| | - Ralph N. Martins
- Department of Biomedical SciencesMacquarie UniversityNorth RydeNew South WalesAustralia
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- School of Psychiatry and Clinical NeurosciencesUniversity of Western AustraliaCrawleyWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
- The Cooperative Research Centre for Mental HealthCarlton SouthVictoriaAustralia
| | - Hamid R. Sohrabi
- Department of Biomedical SciencesMacquarie UniversityNorth RydeNew South WalesAustralia
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- School of Psychiatry and Clinical NeurosciencesUniversity of Western AustraliaCrawleyWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
- The Cooperative Research Centre for Mental HealthCarlton SouthVictoriaAustralia
| | - Kevin Taddei
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
| | - Victor L. Villemagne
- Department of Molecular Imaging and TherapyAustin HealthMelbourneVictoriaAustralia
| | - Peter R. Schofield
- Neuroscience Research Australia, RandwickSydneyNew South WalesAustralia
- School of Medical SciencesUNSW SydneySydneyNew South WalesAustralia
| | - William S. Brooks
- Neuroscience Research Australia, RandwickSydneyNew South WalesAustralia
- Prince of Wales Hospital Clinical SchoolUNSW SydneySydneyNew South WalesAustralia
| | - Michael Fulham
- Department of Molecular Imaging, Royal Prince Alfred Hospital, Sydney Medical SchoolUniversity of SydneyCamperdownNew South WalesAustralia
| | - Colin L. Masters
- The Florey InstituteUniversity of MelbourneParkvilleVictoriaAustralia
| | - Bernardino Ghetti
- Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisIndianaUSA
| | - Andrew J. Saykin
- Department of NeurologyIndiana University School of MedicineIndianapolisIndianaUSA
- Department of RadiologyIndiana University School of MedicineIndianapolisIndianaUSA
| | | | | | - Michael Weiner
- Department of Veterans Affairs Medical CenterCenter for Imaging of Neurodegenerative DiseasesSan FranciscoCaliforniaUSA
- Department of RadiologyUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
- Department of MedicineUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
- Department of PsychiatryUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
- Department of NeurologyUniversity of California, San FranciscoSan FranciscoCaliforniaUSA
| | - David M. Cash
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of NeurologyUniversity College LondonLondonUK
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical EngineeringUniversity College LondonLondonUK
| | - Ricardo F. Allegri
- Department of Cognitive Neurology, Neuropsychiatry and NeuropsychologyInstituto de InvestigacionesNeurológicas FLENIBuenos AiresArgentina
| | - Patricio Chrem
- Department of Cognitive Neurology, Neuropsychiatry and NeuropsychologyInstituto de InvestigacionesNeurológicas FLENIBuenos AiresArgentina
| | - Su Yi
- Banner Alzheimer's InstitutePhoenixArizonaUSA
| | - Bruce L. Miller
- Global Brain Health InstituteUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Department of Neurology, Memory and Aging CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Gil D. Rabinovici
- Global Brain Health InstituteUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | - Howard J. Rosen
- Global Brain Health InstituteUniversity of CaliforniaSan FranciscoCaliforniaUSA
- Department of Neurology, Memory and Aging CenterUniversity of CaliforniaSan FranciscoCaliforniaUSA
| | | |
Collapse
|
14
|
Joseph‐Mathurin N, Kantarci K, Jack CR, Ringman JM, Salloway S, McDade E, Clifford D, Blazey T, Friedrichsen KA, Su Y, Gordon BA, Hornbeck RC, Mills S, Ances BM, Raichle ME, Marcus DS, Cairns NJ, Xiong C, Cruchaga C, Goate A, Buckles V, Paumier KL, Morris JC, Bateman RJ, Benzinger TL. [IC‐P‐057]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
| | | | | | | | | | - Eric McDade
- Washington University School of MedicineSt. LouisMOUSA
| | | | - Tyler Blazey
- Washington University School of MedicineSt. LouisMOUSA
| | | | - Yi Su
- Washington University School of MedicineSt. LouisMOUSA
| | | | | | - Susan Mills
- Washington University School of MedicineSt. LouisMOUSA
| | - Beau M. Ances
- Washington University School of MedicineSt. LouisMOUSA
| | | | | | | | | | | | - Alison Goate
- Icahn School of Medicine at Mount SinaiNew YorkNYUSA
| | | | | | | | | | | | | |
Collapse
|
15
|
Joseph‐Mathurin N, Kantarci K, Jack CR, Ringman JM, Salloway S, McDade E, Clifford D, Blazey T, Friedrichsen KA, Su Y, Gordon BA, Hornbeck RC, Mills S, Ances BM, Raichle ME, Marcus DS, Cairns NJ, Xiong C, Cruchaga C, Goate A, Buckles V, Paumier KL, Morris JC, Bateman RJ, Benzinger TL. [O1–02–04]: CLINICAL RISK RELATED TO CEREBRAL MICROHEMORRHAGES IN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE: LONGITUDINAL RESULTS FROM THE DIAN STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.07.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | | | | | | | | | - Eric McDade
- Washington University School of MedicineSt. LouisMOUSA
| | | | - Tyler Blazey
- Washington University School of MedicineSt. LouisMOUSA
| | | | - Yi Su
- Washington University School of MedicineSt. LouisMOUSA
| | | | | | - Susan Mills
- Washington University School of MedicineSt. LouisMOUSA
| | - Beau M. Ances
- Washington University School of MedicineSt. LouisMOUSA
| | | | | | | | | | | | - Alison Goate
- Washington University School of MedicineSt. LouisMOUSA
| | | | - Katrina L. Paumier
- Washington University School of MedicineSt. LouisMOUSA
- Icahn School of Medicine at Mount SinaiNew YorkNYUSA
| | - John C. Morris
- Washington University School of MedicineSt. LouisMOUSA
- Alpert Medical School of Brown UniversityProvidenceRIUSA
| | - Randall J. Bateman
- Washington University School of MedicineSt. LouisMOUSA
- University of Southern CaliforniaLos AngelesCAUSA
| | - Tammie L.S. Benzinger
- Washington University School of MedicineSt. LouisMOUSA
- Mayo Clinic College of MedicineRochesterMNUSA
| | | |
Collapse
|
16
|
Joseph‐Mathurin N, Su Y, Blazey T, Jasielec MS, Vlassenko AG, Friedrichsen KA, Gordon BA, Hornbeck RC, Cash L, Ances BM, Raichle ME, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Fagan AM, Goate A, Jack CR, Klunk BE, Koeppe RA, Marcus DS, Mayeux R, McDade E, Paumier KL, Ringman JM, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TL. [IC‐P‐166]: UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER's DISEASE POPULATION: REPORT FROM THE DIAN STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.2541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - Yi Su
- Washington University School of MedicineSt. LouisMOUSA
| | - Tyler Blazey
- Washington University School of MedicineSt. LouisMOUSA
| | | | | | | | | | | | - Lisa Cash
- Washington University School of MedicineSt. LouisMOUSA
| | - Beau M. Ances
- Washington University School of MedicineSt. LouisMOUSA
| | | | - Adam M. Brickman
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia UniversityNew YorkNYUSA
| | | | | | | | - Anne M. Fagan
- Washington University School of MedicineSt. LouisMOUSA
| | - Alison Goate
- Icahn School of Medicine at Mount SinaiNew YorkNYUSA
| | | | | | | | | | | | - Eric McDade
- Washington University School of MedicineSt. LouisMOUSA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Wang Q, Blazey T, Joseph‐Mathurin N, Morris JC, Benzinger T. IC‐P‐060: REVEALING WHITE MATTER ABNORMALITY BY DIFFUSION TENSOR MAGNETIC RESONANCE IMAGING BEFORE THE ONSET OF DEMENTIA IN ALZHEIMER DISEASE. Alzheimers Dement 2014. [DOI: 10.1016/j.jalz.2014.05.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Qing Wang
- Washington University School of MedicineSt. LouisMissouriUnited States
| | - Tyler Blazey
- Washington University School of MedicineSt. LouisMissouriUnited States
| | | | | | | |
Collapse
|
18
|
Daorieux ON, Joseph‐Mathurin N, Chaigneau M, Guillermier M, Houitte D, Josephine C, David Santin M, Kraska A, Van‐Camp N, Phillippe H, Metzker F, Perret M, Dhenain M. P2‐002:
In‐vivo
detection of age‐related cerebral glucose uptake alterations by pet in microcebus murinus primates. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.2437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Joseph‐Mathurin N, Dorieux O, Kraska A, Santin M, Trouche S, Boutajangout A, Hantraye P, Verdier J, Sigurdsson E, Mestre‐Frances N, Dhenain M. IC‐P‐087: In vivo follow‐up of cerebral aging and side effects of anti‐amyloid immunotherapies in the mouse lemur primate. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Marc Dhenain
- URA CEA‐CNRS 2210 MIRCenFontenay‐aux‐RosesFrance
| |
Collapse
|
20
|
Santin M, Petiet A, Bertrand A, Petit F, Dorieux O, Kraska A, Joseph‐Mathurin N, Philippe H, Rooney T, Debeir T, Dhenain M. IC‐P‐137: Longitudinal
in vivo
micro‐anatomic followup of amyloid plaque load by MRI. Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
21
|
Kraska A, Santin M, Dhenain M, Philippe H, Dorieux O, Chaigneau M, Guillermier M, Houitte D, Josephine C, Perret M, Joseph‐Mathurin N, Aujard F, Lestage P. O1‐03‐07: MRI evaluation of focal brain lesions in streptozotocin‐treated animals: Comparison between rodents (rats) and primates (microcebus murinus). Alzheimers Dement 2011. [DOI: 10.1016/j.jalz.2011.05.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Audrey Kraska
- URA CEA‐CNRS 2210 MIRCenFontenay‐aux‐RosesPantinFrance
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|